Medtronic is to spend up to $500m on three companies in a bid to bolster its European peripheral vascular disease portfolio. The firm is set to buy Invatec, an Italian developer of interventional cardiovascular disease devices and two of its affiliates: Fogazzi, a family-run ...
Please Login to read the full article.
